Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

The Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research is a Notice of Funding Opportunity (NOFO). It invites applications for grants that propose exploratory research projects. These projects should focus on the advancement and validation of emerging technologies. These technologies should provide unique abilities to target, probe, or assess molecular and cellular features of cancer biology for the purposes of basic or clinical cancer research.

This NOFO is specifically interested in R33 applications, where the technology or method in question has already demonstrated significant feasibility, supported by preliminary data. However, these technologies likely still need more development and stringent validation to garner acceptance and adoption by the wider research community.

Successful applications must show the potential to speed up and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology. They could also address issues related to cancer health disparities.

While the technologies proposed for development should have the potential for widespread use, the focus must be on improving molecular and/or cellular characterisations of cancer. Projects that propose to use existing technologies where the innovation lies in the biological or clinical target/question are not appropriate for this NOFO and will not be considered.

This funding opportunity is part of the broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.